Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jul 4, 2023
Date Accepted: Nov 28, 2023
Date Submitted to PubMed: Nov 28, 2023

The final, peer-reviewed published version of this preprint can be found here:

Supportive Digital Health Service During Cancer Chemotherapy: Single-Arm Before-and-After Feasibility Study

Fridriksdottir N, Ingadottir B, Skúladóttir K, Zoëga S, Gunnarsdóttir S

Supportive Digital Health Service During Cancer Chemotherapy: Single-Arm Before-and-After Feasibility Study

JMIR Form Res 2023;7:e50550

DOI: 10.2196/50550

PMID: 38015268

PMCID: 10770793

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Supportive digital health service during cancer chemotherapy: A single arm before and after feasibility study

  • Nanna Fridriksdottir; 
  • Brynja Ingadottir; 
  • Kristín Skúladóttir; 
  • Sigríður Zoëga; 
  • Sigríður Gunnarsdóttir

ABSTRACT

Background:

A cancer patient portal was designed into the national electronic medical record (EMR) and the public health portal system in Iceland. It consists of remote symptom monitoring with an alert system, delivery of educational material and messaging. At the outset of implementation, a feasibility study was conducted with patients and staff from two treatment teams at Landspitali Cancer Clinic.

Objective:

The study aimed to assess (1) the portal feasibility by adoption, engagement rates, usability, and acceptability, and (2) the preliminary impact and effect sizes of the patient reported portal and secondary outcomes.

Methods:

A continuous sample of patients with at least three chemotherapy administrations planned were invited to use the port and participate in a single arm before and after study. Data on portal engagement, and from the first and final assessments of the ESASr (Edmonton Symptom Assessment Survey revised) and DT&PL (Distress Thermometer & Problem list) the portal PRO´s (Patient Reported Outcomes), were retrieved from medical records. Usability was assessed with the System Usability Scale (SUS) and acceptability with a 35-item agreement scale. Secondary scale measures included perceived quality of life, family support and quality of care, health literacy, health engagement, self-care self-efficacy (SCSE), symptom interference, expected and received knowledge. Healthcare providers (HCP) participated in interviews about the portal feasibility. Data were analyzed with descriptive and inferential statistics.

Results:

Patient portal adoption rate was 72% (103/143) and engagement was 77% (79/103). Mean study time was 8.6 (SD 2.7) weeks. ESASr completion rate was 78% (685/874) and DT&PL 99% (241/242). Patients received a mean of 41(SD 13) information leaflets, 33% initiated messaging, 73% received messages and 85% got phone calls from HCP. The mean usability score was 72.3 (95% CI 68.7-75.3) and was significantly explained by age (β= -0.45), symptom interference (β=0.4), received knowledge (β =0.25), and ESASr engagement (β=0.5). The mean acceptability score was 3.97 (95% CI 3.9- 4.1) and was significantly explained by age (β=-0.31), ESASr engagement (β=0.37), SCSE (β= 0.37), daily symptom interference (β= 0.60) and received knowledge (β=0.41). The ESASr scores improved significantly for total symptom distress (d=0.36), physical (d=0.31) and emotional (d=0.31) intensity, but daily symptom interference increased (d=0.28). Quality of life (d=0.27) and health engagement (d=0.35) improved, and knowledge expectations decreased (d=2.57) significantly. HCP were positive towards the portal and its usability but reported the need for a more detailed role delineation and follow-up.

Conclusions:

This short-term study supports the feasibility of the portal linked to the national EMR and public health port. The results indicate a possibility of improving patient outcomes. Improvements are needed to further the portal’s implementation and impact over a longer period.


 Citation

Please cite as:

Fridriksdottir N, Ingadottir B, Skúladóttir K, Zoëga S, Gunnarsdóttir S

Supportive Digital Health Service During Cancer Chemotherapy: Single-Arm Before-and-After Feasibility Study

JMIR Form Res 2023;7:e50550

DOI: 10.2196/50550

PMID: 38015268

PMCID: 10770793

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.